A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is the key regulator of the fibrinolytic system, thereby acting as a potent mediator in thrombosis. Plasminogen activators such as PAI-1 mediate the conversion of the inactive zymogen plasminogen to plasmin, an active serine protease. As a member of the serpin superfamily, the highly conserved structure of PAI-1 is critical for its regulatory function. This review elucidates PAI-1 structure, function, and genetic architecture, and then discusses intracellular and extracellular functions that have broad implications for proliferative signaling and cell death, angiogenesis, cellular transit, and emerging roles in cancer biology. By understanding the complex and elaborate mechanism of PAI-1 in the fibrinolytic system and as a biomarker, PAI-1 may have broad implications across many disease states not related to its historical roles in fibrinolysis and thrombosis.

 

Scroll to top

Keywords

PAI-1 - extracellular matrix - genetics - fibrinolytic system - cell migration - cell proliferation

The Fibrinolytic System

The human fibrinolytic system plays a pivotal role in hemostasis and thrombosis related to multiple organ systems. At the heart of the proteolytic cascade lie serine proteases—tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA)—responsible for catalyzing the conversion of the zymogen, plasminogen, into the active form, plasmin, through the cleavage of a serine–arginine to valine peptide bond.[1] Plasmin, a key player in the fibrinolytic system, directly catalyzes the degradation of the fibrin protein meshwork that results in the dissolution of thrombi. While tPA primarily facilitates intravascular fibrinolysis through localization of plasminogen and fibrin deposits on the endothelium, uPA is observed predominantly in the pericellular environment, regulating localized proteolysis critical for cell invasion, wound healing, and tumor metastasis.[2] [3] Plasminogen activator inhibitor type 1 (PAI-1), a potent serine protease inhibitor (serpine), plays a significant regulatory role for uPA/tPA to establish an equilibrium between plasminogen and plasmin as well as maintaining a stable pericellular environment for optimal cellular function. Thus, dysregulation of PAI-1 expression leads to multiple downstream pathologies that contribute to coagulopathy and other systemic disease states such as cardiovascular disease, metabolic syndrome, and cancer.[4] Numerous other disease processes include inflammation and infection, diabetes, and neurodegeneration, with PAI-1 associated with aging, skeletal muscle repair, and cellular senescence. PAI-1's role in the fibrinolytic system has clinical relevance, with the excess or deficiency that results in bleeding disorders. Specifically, hyperfibrinolytic disorders can present as bleeding of unknown origin but are largely reported in patients with a PAI-1 deficiency, suggesting a greater need for specific diagnostic testing and timeliness for treatment.[5]

To better recognize the role of PAI-1 as a regulatory checkpoint, it is critical to understand the mechanism of its substrate. uPA is synthesized as an inactive, single-chain zymogen (pro-uPA) composed of 411 amino acids distributed across distinct functional domains: A growth factor domain (GFD; residues 1–49), a Kringle domain (residues 50–131), an interdomain connecting peptide (residues 132–158), and a serine protease domain (residues 150–411).[6] [7] Activation occurs through a single cleavage event at Lys158–Ile159, resulting in a two-chain, active enzyme stabilized by a disulfide bond between Cys148 and Cys279.[8] [9] Subsequent proteolysis can further process uPA, separating the amino-terminal fragment (residues 1–135)—responsible for receptor binding and signaling—from the enzymatic serine protease domain.[8] [9]

The effects of uPA are spatially restricted and amplified through its interactions with its high-affinity receptor, urokinase plasminogen activator receptor (uPAR), or CD87.[10] Belonging to the Ly-6/uPAR superfamily, mature uPAR consists of 283 residues derived from a 335-residue precursor after subsequent signal peptide removal and the addition of a glycosylphosphatidylinositol moiety.[10] [11] Structurally, uPAR is organized into three homologous Ly-6/uPAR/α-neurotoxin-like domains—D1, D2, and D3—which form a central hydrophobic cavity that interacts with the GFD of uPA, inducing conformational changes at the D1–D2 interface that primes the receptor's affinity for secondary ligands, notably vitronectin (VN), a highly abundant protein found in the subendothelial matrix.[11] [12] [13] [14] Crystal structural studies reveal that while uPA occupies the hydrophobic core of uPAR, VN associates externally through its somatomedin domain (SBD; residues 1–44), enabling simultaneous ligand engagement.[12] Binding of uPA shifts uPAR into a closed, high-affinity conformation for VN and initiates intracellular signaling cascades—such as focal adhesion kinase (FAK), the Janus (JAK) and Src family kinases, and the phosphatidylinositol 3-kinase/protein kinase-B (PI3K/Akt) axis—that ultimately culminates in enhanced cytoskeletal remodeling, increased motility, or greater survival signaling.[11] [15]

Given the central role of uPA/uPAR interactions in coordinating cellular processes implicated in the pathogenesis of disease progression, the need for precise regulation is critical, and thus, has garnered the attention of many researchers and clinicians as a potential target to inhibit. Consequently, much of the research has been focused on PAI-1, a key endogenous regulator of uPA that is a part of the serine protease inhibitor superfamily known as serpins. Interestingly, the most peculiar is the bevy of recent literature that has implicated PAI-1 in exerting both promigratory and antimigratory effects independent of its conventionally associated functions within proteolysis. This paradox highlights the complex interplay among these tightly regulated interactions, underscoring perhaps a delicate balance within the cellular microenvironment and the physiological or pathological processes involved. This review aims to summarize our current knowledge on the diverse cellular functions of PAI-1 that have broad implications for emerging roles in cancer biology and therapeutics ([Fig. 1]).

Fig. 1 Overview of the cell-based model of thrombosis and central role for PAI-1 in regulation of fibrinolysis. PAI-1, plasminogen activator inhibitor type 1.

 

Scroll to top

Plasminogen Activator Inhibitor Type 1

Structure, Stability, and Regulation

Glycoprotein PAI-1 is a 45-kDa, 379- to 381-amino acid protein expressed within several tissue beds with a primary role in regulating the fibrinolytic pathway. Being in the serpin superfamily, PAI-1 exhibits a highly conserved structure seen in other serine proteases. Specifically, PAI-1 contains the characteristic three β-sheets (A, B, and C) as well as nine α-helices (hA–hI) that are typical of this family of proteases. Critical for its function, a reactive center loop (RCL) composed of 26 residues (331-SGTVASSSTAVIVSARMAPEEIIMDR-356) is critical to its function as a plasminogen inhibitor ([Fig. 2]).[16] [17] [18] This sequence is particularly important at Arg346 and Met347 (P1-P1′) due to its role as a substrate mimic toward tPA and uPA. The remainder of the RCL sequence is thus referred to as P16-P10′ regarding its position around these key residues. Importantly, the P16-P10′ region confers specificity to the individual proteins within the serpine family.

Fig. 2 Protein structure of plasminogen activator inhibitor type 1 with reactive center loop highlighted and labeled residues. Molecular graphics and analyses performed with University of California, San Francisco (UCSF) ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases.[18]

The remainder of the amino acids outside this region are highly conserved among this superfamily of proteins, and mutagenic studies have confirmed that alteration of the RCL changes its function. Specifically, studies indicate that mutations in the P1-P1′ region can alter the structure to act as antithrombin III depending on the alterations made to the base sequence.[19] [20] [21] As a target-specific region, PAI-1 selectively inhibits plasminogen activators (PAs) to perform its role as an antifibrinolytic agent.

PAI-1 is highly expressed in many tissues, such as the liver, respiratory system, kidneys, placenta, vascular smooth muscle cells, endothelial cells, and adipose tissue. Once secreted into the circulation, it exists in an active conformation for only a few minutes (plasma t _1/2 6 minutes) before being rapidly cleared by the liver.[22] Structurally, PAI-1 exists in two forms, active and latent, which modulate its activity toward PA in a conformationally dependent manner. Once PAI-1 is secreted by endothelial cells, it exists in two main reservoirs intravascularly—free plasma, and retained in circulating platelets. The free plasma concentration is predominantly in an active conformation but only accounts for as much as 5 to 50 ng/mL in serum.[23] Conversely, platelet retained PAI-1 accounts for much higher levels up to 300 ng/mL but exhibits mostly latent conformation.[23] Interestingly, research has indicated that platelet activation induced by endothelial damage shows a significant increase in the active form of PAI-1. This presents a benefit to reinforcing clot formation at the onset of damage to ensure proper hemodynamic stability during times of injury.

PAI-1 exerts its effects in a tissue-specific manner due to glycosylation at Asn209 and Asn265 and its interaction with local mediators like PA.[23] Inhibitory members of the serpin family, such as PAI-1, interact through the formation of a covalent 1:1 stoichiometric complex with their target proteinases.[24] Formation of an ester bond between the carboxyl group of the P1 residue of the serpin and the hydroxyl group of the active serine residue of the target protease inhibits the activity of the target protease.[24] The crystal structure of latent PAI-1 was originally elucidated by Mottonen et al in 1992, followed by determination of the crystal structure of active PAI-1 by Nar et al.[25] [26] Structure–function experimentation has revealed that the major, biologically relevant difference between latent and active forms of PAI-1 is that active PAI-1 has an exposed bait region (P1-P1′; [Fig. 2]) known as an RCL (R346-M347), as well as accessible secondary binding sites that enable inhibitory complex formation with a target protease. In latent PAI-1, the bait region and secondary structures are inaccessible and cannot bind to the active site of serine proteases.[23] The active conformation of PAI-1 in human tissue is maintained by complexing with VN, a highly abundant protein found in the subendothelial matrix. It is likely that VN-bound PAI-1 ([Fig. 3]) is the physiologically relevant mechanism for maintaining the inhibitory function of PAI-1 in human tissue. Importantly, the structural characteristics of PAI-1 present key interactions that can be leveraged during the development of effective therapeutics discussed later in this review.

Fig. 3 Protein structure of PAI-1 and somatomedin B domain of vitronectin with resultant depiction of protein–protein binding of PAI-1/vitronectin complex. Coloring of the protein surface indicates polarity of acidic (red), alkaline (blue), and uncharged (white) side chains. Vitronectin is composed of relatively acidic R groups that interact strongly with PAI-1's alkaline-binding pocket.[18] PAI-1, plasminogen activator inhibitor type 1.

Recognizing the importance of the RCL to PAI-1's function, it is critical to elucidate the mechanisms surrounding this inhibitory process of PAs. Specifically, two major pathways exist once RCL interacts with the PA active site: The irreversible inhibitory pathway and the substrate pathway. Prior to entering a specific sequence, the RCL chain first binds to PA, forming a weak, non-covalent Michaelis complex.[17] [23] [27] [28] This step is followed by attack of the PA active site serine (tPA-Ser478 or uPA195) onto the RCL to produce an unstable tetrahedral intermediate with PAI-1.[17] [29] The tetrahedral intermediate undergoes subsequent collapse that forms a more stable acyl–enzyme intermediate with resultant covalently bound PAI-1/PA complex.[30] [31] From the acyl–enzyme complex, PAI-1 activity induces either the irreversible inhibitory or substrate pathway. Importantly, the inhibitory sequence accounts for most PAI-1 interactions and follows a complex rearrangement of three-dimensional structure. Crystal structure analysis indicates that the high-energy state of acyl-intermediate formation encourages protein rearrangement to a lower-energy conformation that results in shifting of the P16-P1 portion (N-terminal side) into the core β-sheet of PAI-1.[29] The thermodynamically driven rearrangement ultimately fuels the compression of PA against the core of PAI-1, leading to effective blocking of its active site.[32] Resultant deformation of PA thus prevents hydrolysis of the PAI-1/PA complex and yields an irreversible inhibition of function.[30] [31] Conversely, reports have identified an alternative substrate pathway that effectively regenerates PA after the formation of the acyl–enzyme intermediate. It is proposed that hydrolysis occurs prior to PA deformation in the core of PAI-1, which releases PA before the P16-P1 region and can undergo conformational change.[17] [23] [33] [34] It is thought that a distinct subset of PAI-1 in this alternative substrate pathway exists or can be induced through local intermediaries or kinetic properties, which could precipitate more active PA.[35] [36] [37] [38]

Interestingly, PAI-1 regulation centers on deactivating the RCL through conformational change from the active-to-latent transition. Studies have shown that the in vitro half-life of the active conformer of PAI-1 is around 2 hours and occurs through a slow, self-insertion of the N-terminal region of the RCL into the core protein.[17] [26] This insertion functionally blocks the P1-P1′ region from interacting with PAs such as tPA and uPA. It is hypothesized that this form of autoregulation presents an ancestral benefit in reducing the risk of thrombosis due to otherwise extended antifibrinolytic activity of PAI-1.[16] [17] Additionally, in vivo analysis of PAI-1 stability has been extensively studied and relies upon interaction with the ubiquitous plasma glycoprotein, VN. VN, as discussed throughout this review, serves as a cofactor for PAI-1 and stabilizes its active form, approximately twofold, through stabilization of the lower half of its protein structure without affecting enzymatic activity to regulate PA.[39] [40] [41] [42] This stabilization ultimately slows the conversion to latent-type PAI-1 and serves as an important barrier to keep in mind during the development of therapeutic targets.

 

Scroll to top

Genetic Architecture

PAI-1 is encoded by the SERPINE1 gene, located on chromosome 7q21.3-q22 (NCBI accession number M16006). This gene spans approximately 12.3 kb and consists of nine exons and eight introns, as shown ([Fig. 4]).[22] [43] [44] [45] [46] [47] [48] [49] [50] [51] Two distinct mRNA transcripts, 2.3 and 3.2 kb in length, are produced from this gene due to alternative polyadenylation, with the longer transcript potentially exhibiting greater stability due to an AT-rich sequence.[52]

Fig. 4 Schematic representation of the SERPINE1 gene structure. The SERPINE1 gene, encoding plasminogen activator inhibitor type 1, is located on chromosome 7q21.3-q22 and spans approximately 12.3 kb. The gene consists of nine exons (blue boxes) and eight introns (connecting lines). The 4G/5G polymorphism is shown at −675 bases upstream of the transcriptional start site.

The 5′ promoter region of the PAI-1 gene is a complex landscape of regulatory elements with significant implications in cardiovascular disease ([Fig. 5]).[43] [44] [52] In the presence of wound healing, p38 mitogen-activated protein kinase (MAPK) is rapidly activated in the MAP kinase pathways in cells adjacent to the injury, leading to phosphorylation of the transcription factor upstream stimulatory factor-1 (USF-1), a member of the helix–loop–helix family. This phosphorylated USF-1 complex then translocates to the nucleus, where it binds to the E-box motif (CACGTG sequence located at nucleotides −160 to −165) in the proximal promoter region of the PAI-1 gene; this binding is essential for upregulation of PAI-1 transcription. Notably, activator protein-1 (AP-1)-binding sites do not play a significant role in the PAI-1 regulation model, with the MAPK–USF-1 axis the primary pathway linking mechanical injury to PAI-1 gene activation.[53] This pathway is not only active in wound healing, but is a critical player in vascular injury response and cardiovascular disease.[47] [53] During vascular injury due to shearing, inflammation, and diabetes, the MAPK–USF-1 pathway is activated as described above, promoting the upregulation of PAI-1 transcription. Additionally, the presence of a glucocorticoid response element site enables upregulation of PAI-1 expression by glucocorticoids like dexamethasone and mineralocorticoids like aldosterone.[43] [54] [55] This is particularly relevant in hypertension, where angiotensin II stimulates PAI-1 expression and release, which can be further amplified by glucocorticoids and aldosterone.[43] [54] [56] A VLDL response element situated within the PAI-1 promoter region at positions −672 to −657 facilitates interaction with very low density lipoprotein (VLDL), a lipoprotein often elevated in diabetes and metabolic syndrome, suggesting potential clinical implications for these conditions.[43] [57] [58] Sp1 sites in the promoter region are positively regulated by glucose and glucosamine, linking elevated glucose levels to increased PAI-1 levels, and potentially contributing to the development of diabetes.[43] [59] [60] Additionally, the presence of Smad-binding element and p53-responsive element in the PAI-1 promoter suggests potential involvement in various cancers.[43] [61] [62]

Fig. 5 Schematic representation of the 5′ promoter region of the PAI-1 gene and its regulatory elements. The PAI-1 promoter contains multiple transcriptional regulatory elements influencing gene expression. The −675 4G/5G polymorphism (yellow) is associated with higher expression. A VLDL response element (−672 to −657, black) links PAI-1 expression to lipid metabolism. Smad-binding elements (red) at −730, −580, and −280 indicate TGF-β/Smad pathway regulation. A p53-responsive element (−160 to −139, green) suggests a role in cellular stress responses and tumorigenesis. Sp1-binding sites (−118, −73, −42, light blue) mediate glucose-induced upregulation. A glucocorticoid response element (GRE; −73, dark blue) suggests modulation by glucocorticoids. The TATA box (−28, gray) is essential for transcription initiation. PAI-1, plasminogen activator inhibitor type 1.

Another important aspect of the PAI-1 promoter is the −675 4G/5G polymorphism. This insertion/deletion polymorphism affects PAI-1 levels, with the 4G allele associated with higher levels than the 5G allele.[43] [63] [64] [65] Although the exact clinical consequences of this polymorphism are under debate, its association with various diseases, including stroke and venous thromboembolism, emphasizes the significance of PAI-1 in a wide range of clinical conditions.[43] [66] Collectively, these conserved regulatory elements provide insights into the mechanisms that modulate PAI-1 levels and function in vivo and influence various clinical conditions ranging from cardiovascular diseases and metabolic disorders to cancer. Understanding these regulatory mechanisms enhances our grasp of PAI-1's role as both a biomarker and a potential therapeutic target across different disease states characterized by thrombotic risk and altered fibrinolysis.

 

Scroll to top

Intracellular and Extracellular Functions

It is extensively characterized that the uPA/uPAR system plays a central role in tightly regulating extracellular matrix (ECM) remodeling essential for supporting cell migration. Disruption of this balance can have pathological consequences.[11] [67] [68] [69] Excessive ECM degradation leads to compromised structural integrity and enhanced cell invasion, while insufficient matrix turnover results in abnormal ECM accumulation and impaired cellular dynamics.[9] [68] Early studies substantiate that PAI-1 critically modulates ECM dynamics by interacting with multiple extracellular components, including PAs, VN, and low-density lipoprotein receptor-related protein 1 (LRP1).[70] [71] [72] [73] Through these interactions, PAI-1 has been shown to both inhibit and promote cell migration depending on the contextual molecular environment.[68] [71] [74]

 

Scroll to top

Regulation of Plasmin Generation

One of the major functions of PAI-1 is its ability to modulate coagulation through its interaction with tPA and uPA. By blocking tPA/uPA agonist activity on the conversion of plasminogen to plasmin, PAI-1 effectively inhibits fibrinolysis through a deficiency of plasmin levels.[75] In the absence of PAI-1, uPA bound to uPAR and tPA/fibrin activates plasminogen through cleavage of Arg561–Val562 residues of each proenzyme.[75] This cleavage results in the generation of plasmin, which binds to fibrin to produce fibrin degradation products. Mechanistically, PAI-1's binding to uPA/tPA (as described above) leads to the collapse of the tPA and uPA active site for plasminogen. Therefore, plasminogen is unable to effectively bind and undergo cleavage into plasmin products. Interestingly, research on patients with homozygous PAI-1 deficiency exhibited increased peak plasmin levels and resulted in hyperfibrinolytic bleeding.[76] Due to its effective inhibition of tPA/uPA as well as its rapid onset of action when released, PAI-1 remains a critical component of the balance between coagulation and fibrinolysis.

 

Scroll to top

Plasminogen Activator Inhibitor Type 1 and Vitronectin: A Central Player in Cell Migration through Urokinase Plasminogen Activator Receptor

VN is established to play a pivotal role in this process. The somatomedin B domain of VN binds to PAI-1, stabilizing its active conformation and enhancing its inhibitory effect on uPA-dependent proteolysis, thereby reducing ECM degradation and limiting the cellular ability to migrate and invade.[77] [78] Furthermore, PAI-1 exhibits a stronger binding affinity to the SMB domain of VN compared with uPAR.[71] During binding of the somatomedin B domain of VN, PAI-1 structurally distorts the arginine-glycine-aspartate (RGD) sequence of VN, the primary binding site for αvβ3 integrins, affecting the formation and turnover of focal adhesions, essential for cell migration.[24] [69] This competitive binding is a key mechanism through which PAI-1 indirectly modulates integrin function without directly binding to the integrins themselves.[72] As a result, elevated levels of PAI-1 can lead to detachment of cells from VN-rich matrices by blocking integrin-mediated adhesion, promoting cell motility or dysmotility in certain contexts.[72]

PAI-1 also contributes to cell signaling through its effects on uPAR–integrin associations. The binding of uPA to uPAR promotes the assembly of uPAR–integrin complexes, which in turn facilitates the activation of FAK and Src family kinases through caveolin-mediated clustering at the cell surface.[9] [15] These complexes are necessary for initiating adhesion-dependent signal transduction.[9] [15] Disruption of uPAR–integrin interactions by PAI-1, through VN competition, impairs this signaling cascade.[79] [80] Notably, excessive uPAR activity has also been shown to drive extracellular-signal related kinase (ERK) activation and exit from tumor dormancy by promoting α5β1-dependent FAK/Src signaling.[81] Thus, PAI-1-mediated interference with uPAR–integrin clustering may serve as a regulatory checkpoint in these pathways.

Furthermore, PAI-1 indirectly influences G-protein-coupled receptor signaling via its control over uPAR cleavage. When uPA binds to uPAR or when the D1 domain is proteolytically removed, a chemotactic epitope (Ser88–Tyr92) becomes exposed, allowing the receptor to engage G-protein coupled receptors (GPCRs) such as formyl peptide receptor-like 1.[82] [83] [84] [85] [86] [87] These interactions promote cytoskeletal rearrangement and cell movement in a pertussis toxin-sensitive manner.[88] By modulating uPAR availability and surface retention, PAI-1 can indirectly regulate the activation of these chemotactic pathways.

Experimental studies have further confirmed the relevance of PAI-1–integrin dynamics to cell movement. Treatment of cells with recombinant PAI-1 mimics the effects of αvβ5 integrin blockade, resulting in cell detachment from VN and enhanced migration toward other ECM proteins such as fibronectin or collagen type IV.[72] [79] [89] These findings highlight PAI-1's ability to remodel adhesion patterns by interfering with integrin–ECM engagement, independent of its classical role as a serine protease inhibitor. Further investigations by Sathyamoorthy et al[90] employed RNA interference to inhibit PAI-1 expression in HL-60 human monocytes. Transfection of small interfering RNAs targeting PAI-1 mRNA achieved an 85% reduction in PAI-1 mRNA and complete inhibition of glycosylated PAI-1 protein expression after 72 hours.[90] This posttranscriptional silencing revealed a significant increase in monocyte adhesion attributable to enhanced interactions between VN and its receptors. Further investigations by Sathyamoorthy et al[91] demonstrated the role of PAI-1 in endothelial progenitor cell (EPC) regulation. Using bone marrow-derived EPCs from wild-type and PAI-1-deficient mice, they found that PAI-1 deficiency led to a 75% increase in early outgrowth EPCs and enhanced proliferative capacity.[91] Similarly, in a model of chronic vascular injury using N()- nitro-L-arginine methyl ester (L-NAME), PAI-1-deficient mice showed a 65% increase in circulating EPCs in comparison to c57BL6 wild-type controls.[91] These results suggest that PAI-1 deficiency can enhance EPC proliferation and mobilization, potentially offering protective effects against vascular injury.

Conversely, PAI-1 has also been reported to promote cell migration by protecting the ECM against excessive plasmin-mediated degradation, providing a provisional matrix that tumor and endothelial cells use as a scaffold for migration or capillary formation.[68] [92] In fact, a recent study by McCann et al demonstrated that a decrease in TGF-β signaling caused a decrease in miR-30 expression, which subsequently resulted in the upregulation of PAI-1, decreased uPA activity, and fibrin-mediated angiogenesis.[93] Restoration experiments in PAI-1-deficient mice confirmed that reintroducing recombinant PAI-1—particularly functional at the VN-binding site—could restore tumor angiogenesis, further highlighting the dual requirement for matrix preservation and controlled proteolysis during new vessel formation.[94] [95] Collectively, these studies underscore the context-dependent nature of PAI-1 in cell migration, suggesting that the relative stoichiometry of PAI-1, VN, and uPA, as well as the other factors in the cell microenvironment, significantly influences these processes.

 

Scroll to top

Plasminogen Activator Inhibitor Type 1 and Low-Density Lipoprotein Receptor-Related Protein 1-Mediated Endocytosis and Integrin Regulation

Beyond its interaction with VN, PAI-1 can influence cell migration through its interaction with LRP1, a member of the LDL receptor family.[96] The low-density lipoprotein receptor-related protein family is involved in numerous physiological processes such as regulating cholesterol homeostasis and lipid transport, supporting brain development and function, facilitating nutrient and vitamin transport, aiding the uptake of essential molecules, and participating in signal transduction.[97]

Following uPA/PAI's detachment from VN, the cryptic receptor-binding site of PAI-1 becomes exposed, allowing the molecule to bind to LRP1.[59] [60] [61] This interaction initiates endocytosis of the uPA/uPAR/PAI-1 complex along with associated integrins. Inside the cell, PAI-1 and uPA are targeted for lysosomal degradation, while uPAR and LRP1 are recycled back to the plasma membrane, particularly at the leading edge of migrating cells.[9] [98] [99] [100] This recycling process enables cells to establish new adhesion points in different ECM regions, contributing to persistent migration across tissue substrates. Notably, while LRP1-mediated integrin endocytosis can occur, it is not strictly required for PAI-1-initiated cell detachment, suggesting that PAI-1 can promote cell detachment through multiple mechanisms, not solely dependent on LRP1-mediated integrin internalization.[98] Despite losing their antiprotease activity, latent or cleaved forms of PAI-1 retain the capacity to bind to LRP1 independently and promote cell migration.[96] [101] [102] These forms can, therefore, remain embedded in the ECM, potentially serving as a reservoir for active PAI-1 to maintain cell movement.[103]

LRP1 plays a dual role in endocytosis and signal transduction. PAI-1 facilitates the internalization of uPA/uPAR complexes by binding LRP1 via its cryptic receptor-binding domain exposed after detachment from VN.[68] [104] In doing so, PAI-1 regulates receptor trafficking while also modulating intracellular signaling. Studies have shown that LRP1 suppresses Rac1 and ERK activation in an uPAR-dependent manner.[73] [96] [105] In LRP1-deficient mouse embryonic fibroblasts or in cells treated with receptor-associated protein to block LRP1, Rac1 activity, and cell motility increase—an effect absent from uPAR-knockout cells, confirming the requirement of uPAR for this pathway.[106] By controlling LRP1-mediated trafficking, PAI-1 thus influences Rho GTPase-driven cytoskeletal dynamics and downstream MAPK activation, which in turn leads to cytoskeletal rearrangements, including the formation of lamellipodia and filopodia, which are essential for cell motility.

PAI-1 also plays a role in modulating intracellular signaling through the JAK/STAT pathway, albeit indirectly, by regulating the availability and clustering of the uPA/uPAR complex at the cell surface. When uPA binds uPAR, receptor clustering can recruit JAK1 and activate STAT1, leading to STAT1 dimerization, nuclear translocation, and transcription of target genes via interferon-γ activation site and interferon-stimulated response elements.[74] This signaling is facilitated by co-localization with gp130.[74] [107] By inhibiting uPA binding and promoting internalization of uPA/uPAR complexes through LRP1, PAI-1 reduces surface receptor density and attenuates JAK/STAT activation. These effects have been observed in epithelial and vascular smooth muscle cells where PAI-1 influences migration and gene expression through upstream control of this pathway.[108] [109]

The intricate interplay between the components of the uPA system, particularly the multifaceted role of PAI-1, emphasizes the complexity of cell migration regulation. PAI-1's ability to influence cell behavior through interactions with uPA, its receptor uPAR, LRP1, integrins, and VN highlights its significance as a potential therapeutic target in diseases characterized by dysregulated cell migration and ECM remodelling. While PAI-1 inhibition of uPA-mediated proteolysis can suppress cell migration, its interactions with other molecules like VN and LRP1 can promote cell detachment and signaling, leading to increased motility. This dual nature of PAI-1 explains the paradoxical observations in clinical settings, which have been observed to be associated with high levels of PAI-1 with poor prognosis in specific cancer patient populations.[110] [111] [112]

 

Scroll to top

Sustaining Proliferative Signaling

Building on its established role in ECM regulation and modulation of uPA/uPAR signaling, PAI-1 also contributes to proliferative signaling in cancer by shaping the extracellular and pericellular environments that control receptor activation. While some studies have shown PAI-1 to inhibit proliferation in certain cancer types, like hepatocellular carcinoma,[92] ovarian,[113] and prostate cancer,[92] most research indicates that PAI-1 promotes cancer cell proliferation through various mechanisms.[114] [115] Giacoia et al demonstrated that PAI-1 downregulation inhibited cell proliferation by inducing G0–G1 cell cycle arrest, whereas PAI-1 overexpression enhanced S-phase entry and increased tumor size in xenograft models.[116] This is consistent with findings by Mashiko et al, who demonstrated that PAI-1 knockdown or inhibition blocked ovarian cancer cell proliferation through G2–M cell cycle arrest and intrinsic apoptosis.[117] Similarly, Li et al found that PAI-1 acts as a tumor enhancer in aggressive fibromatosis but reduces tumor cell proliferation and motility when deficient.[118]

These proliferative effects are largely mediated through PAI-1's indirect influence on surface receptor availability and proteolytic microenvironment. By inhibiting uPA- and tPA-mediated plasminogen activation, PAI-1 limits plasmin generation and maintains thrombin activity in the tumor microenvironment. Elevated thrombin levels can activate protease-activated receptors (PARs), particularly PAR-1 and PAR-2, which are G-protein-coupled receptors implicated in tumor cell proliferation, migration, and angiogenesis.[119] [120] [121] Thrombin-induced PAR-1 activation triggers intracellular signaling via MAPK/ERK and PI3K/Akt pathways, linking PAI-1-mediated fibrinolytic suppression to enhanced mitogenic responses. Furthermore, PAI-1 fibronectin-dependent cell growth by regulating cell detachment from VN and adhesion to fibronectin.[120] [121] PAI-1 also modulates growth factor receptor signaling by affecting uPA/uPAR complex dynamics. Stabilization or clearance of these complexes can influence epidermal growth factor receptor (EGFR) activation, as well as ERK and AKT signaling, as observed in lung fibroblasts.[122] In other contexts, such as neuronal cells, PAI-1 enhances nerve growth factor-mediated responses by maintaining the proteolytic balance necessary for receptor engagement.[123]

Despite these growth-promoting roles, PAI-1 can also induce senescence or dormancy under stress or in the presence of p53 activation.[124] [125] [126] PAI-1 is a well-established transcriptional target of p53, and its upregulation is essential for enforcing p53-mediated replicative senescence. Kortlever et al demonstrated that PAI-1 expression alone was sufficient to induce a senescent phenotype in fibroblast cells even in the absence of functional p53, permitting cells to bypass senescence.[124] Mechanistically, PAI-1 has been shown to inhibit proteasome activity, resulting in stabilization of p53 and sustained activation of the p53–p21–pRb axis, thereby enforcing irreversible cell cycle arrest.[124] Aguirre-Ghiso et al showed that PAI-1 inhibition of uPA/uPAR activity can induce tumor cell dormancy by altering the ERK/p38 activity ratio.[127] Kubala and DeClerck[92] highlighted this ongoing controversy, stating that while some studies[116] show that PAI-1 stimulates cell cycle progression through cyclin D3/CDK4/6 upregulation, other studies[128] indicate PAI-1 has an inhibitory function on proliferation in breast cancer cell lines. Thus, without a precise molecular mechanism identified, the direct impact of PAI-1 on tumor cell cycles remains a subject of debate.

 

Scroll to top

Resisting Cell Death

PAI-1 contributes to tumor cell survival by modulating apoptosis through both indirect protease inhibition and direct intracellular signaling mechanisms. PAI-1 has been shown to suppress both extrinsic and intrinsic apoptotic pathways.[129] Extrinsically, it protects cells from Fas-mediated apoptosis by regulating pericellular plasmin activity, thereby preventing the cleavage and shedding of Fas ligand (FasL) in various human cancer cell lines.[129] [130] [131] This function is primarily mediated through PAI-1's ability to inhibit uPA and maintain low plasmin levels, thereby preventing proteolytic activation of proapoptotic pathways.

Intrinsically, PAI-1 has been shown to interact with and inhibit caspase-3, a key executioner of apoptosis, as demonstrated in vascular smooth muscle cells and endothelial models.[129] [132] [133] This inhibition may occur through a cross-class serpin mechanism involving the RCL of PAI-1, although this interaction remains incompletely defined. Furthermore, PAI-1 has been shown to upregulate antiapoptotic proteins, such as B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL), while downregulating proapoptotic proteins, including Bcl-2-associated X protein (Bax) and B-cell lymphoma-extra small (Bcl-xS).[129] [132] [133]

These effects are mediated primarily through activation of the PI3K/Akt and ERK signaling pathways. By promoting the internalization of uPA/uPAR complexes via LRP1, PAI-1 activates PI3K, which phosphorylates and activates Akt.[9] [134] Activated Akt enhances p53 transcriptional activity, suppressing transcription of proapoptotic genes such as Bax while also enhancing the stability and expression of antiapoptotic proteins, Bcl-2 and Bcl-xL. Akt also phosphorylates and inactivates Bad, preventing it from displacing Bcl-2 from its inhibitory complexes. Simultaneously, ERK activation downstream of LRP1 signaling may contribute to transcription of Bcl-2 family genes, supporting cell survival in stress conditions. These pathways have been observed in endothelial and vascular smooth muscle cells in which PAI-1 expression correlates with resistance to serum starvation or detachment-induced apoptosis.[135] [136] Notably, the antiapoptotic activity of PAI-1 can be attenuated using neutralizing antibodies, as demonstrated by Balsara et al, who accelerate its conformational inactivation, suggesting that only the active form of PAI-1 possesses this prosurvival function.[137]

Despite this, several studies indicate that PAI-1's role in apoptosis is not uniformly protective. Depending on the tumor type and microenvironment, PAI-1 overexpression has been associated with increased apoptosis and reduced tumor growth.[138] [139] [140] As seen in certain breast and colon cancer models, PAI-1 overexpression or transfection enhanced apoptotic sensitivity.[130] [141] This functional duality underscores the complexity of PAI-1's role in cancer biology. These multifaceted roles make PAI-1 an important determinant of tumor cell fate and a compelling candidate for targeted therapy in apoptosis-resistant cancers.

 

Scroll to top

Angiogenesis

PAI-1 plays a complex, dose-dependent role in tumor angiogenesis by regulating endothelial cell migration, matrix remodeling, and protease activity through both direct and indirect mechanisms.[95] [140] [142] At physiological concentrations, PAI-1 exhibits proangiogenic activity through multiple mechanisms. It inhibits FasL cleavage by plasmin, preventing Fas-mediated apoptosis in endothelial cells.[143] One mechanism involves inhibition of plasmin-mediated cleavage of FasL, thereby protecting endothelial cells from Fas-dependent apoptosis and allowing sustained angiogenic activity.[94] [130] In parallel, PAI-1 facilitates endothelial migration by disrupting adhesion to VN—through competitive binding at the somatomedin B domain—and promoting movement toward fibronectin-rich areas typical of tumor stroma.[130] [144]

By inhibiting plasminogen activation, PAI-1 contributes to fibrin accumulation, which can enhance endothelial organization and the release of proangiogenic cytokines such as interleukin-8.[145] [146] This matrix stabilization not only provides a scaffold for new vessel formation but also creates a localized environment favorable to cell guidance and alignment during neovascular sprouting.[144] Moreover, PAI-1 promotes interleukin-8-mediated neutrophil transendothelial migration by preventing the proteolytic shedding of IL-8/heparan sulfate/syndecan-1 complexes. By stabilizing IL-8 on the endothelial surface, PAI-1 enhances IL-8 bioavailability and augments its proangiogenic signaling effects.[147] These functions underscore PAI-1's essential role in coordinating immune cell-driven and matrix-dependent processes that support angiogenic remodeling.

Importantly, VEGF-induced activation of uPA on endothelial cells leads to the formation of uPA/PAI-1 complexes on the surface, which are then internalized via LRP1. This internalization is required for targeted recycling of uPAR to the leading edge, a process essential for directional migration during sprouting angiogenesis.[74] The recycling of uPAR was significantly impaired in PAI-1-deficient cells, further underscoring PAI-1's non-proteolytic role in orchestrating the migratory behavior of endothelial cells via receptor trafficking.[74]

Conversely, at supraphysiological concentrations, PAI-1 inhibits angiogenesis by suppressing uPA and plasmin activity, both of which are required for matrix degradation and endothelial invasion. Bajou et al showed in PAI-1 knockout models that normal physiological levels of host-derived PAI-1 are essential for effective tumor vascularization, whereas excessive PAI-1 impairs this process by overly restricting proteolysis.[140] This biphasic behavior explains the paradox wherein PAI-1 is associated with aggressive tumor progression despite its protease-inhibiting function, reflecting its role in maintaining the proteolytic balance needed for controlled angiogenesis. Notably, the cellular source of PAI-1 is a critical determinant of its angiogenic function. Host-derived PAI-1 at physiological concentrations promotes tumor invasion and angiogenesis; whereas, PAI-1 produced by tumor cells, even at high concentrations, cannot compensate for its absence in the host.[140] Transgenic mice overexpressing PAI-1 in tumor cells or tumor cell lines transfected with PAI-1 cDNA exhibited impaired vascularization, suggesting that excessive or localized PAI-1 disrupts the spatial and temporal proteolysis needed for neovessel formation.[140] [148] This suggests that PAI-1's angiogenic function depends not only on its concentration but also on its cellular origin and its ability to regulate endothelial receptor localization, inflammatory signaling, and matrix composition.

 

Scroll to top

 

Scroll to top

Conclusion

Aside from PAI's critical role in the fibrinolytic system as the key natural proteolytic regulator of tPA in plasma, PAI-1 also exhibits numerous intracellular and extracellular functions. PAI-1 is a central player in cell migration and ECM remodeling through the uPA/uPAR system through interaction with multiple extracellular components, including PAs, VN, and LRP1. Given the strong link between uPA–uPAR pathway and PAI-1, with its impact on cellular migration, the need for precise regulation is critical and a potential area for future research as a target for inhibition through small molecules, RNA aptamers, monoclonal antibodies, and repurposed pharmaceuticals.

Additionally, PAI-1 has a significant role in functions including endocytosis, integrin regulation, proliferative signaling, angiogenesis, and invasion and metastasis. Notably, PAI-1 has been shown to have pro- and anticarcinogenic effects, including cell cycle progression through both extrinsic and intrinsic apoptotic pathways, along with cellular senescence and dormancy, highlighting the emerging role of PAI-1 in cancer biology. Even though PAI-1's impact on tumor cell cycles remains a subject of debate, future research can be centered around PAI-1 as a compelling candidate for targeted therapy in apoptosis-resistant cancers. As such, this review advances the understanding of PAI-1's diverse roles in cellular biology and its growing importance in numerous health and human disease states spanning cardiovascular disease to oncology beyond its well-understood historical associations in thrombosis. Our group further highlights PAI's role in neurodegenerative diseases, metabolic disorders, and aging in our subsequent contemporary review of this literature review series.

 

Scroll to top

 

Scroll to top

Conflict of Interest

None declared.

Authors' Contributions

Conceptualization, methodology, formal analysis, investigation M.S., J.W., writing—original draft preparation J.W., J.V., N.S., M.B., M.S., writing—review and editing M.S., J.W., J.V., N.S., M.B., visualization, supervision, project administration, and funding acquisition: M.S.. All authors have read and agreed to the published version of the article.

^* These authors are co-first authors who contributed equally to this article.

• References

• 1 Sottrup-Jensen L, Zajdel M, Claeys H, Petersen TE, Magnusson S. Amino-acid sequence of activation cleavage site in plasminogen: homology with “pro” part of prothrombin. Proc Natl Acad Sci U S A 1975; 72 (07) 2577-2581
• 2 Choong PFM, Nadesapillai APW. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003; ;(415 Suppl): S46-S58
• 3 Macfarlane RG, Pilling J. Fibrinolytic activity of normal urine. Nature 1947; 159 (4049) 779
• 4 Jung RG, Motazedian P, Ramirez FD. et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J 2018; 16: 12
• 5 Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost 2018; (E-pub ahead of print)
• 6 Wang Y, Dang J, Johnson LK, Selhamer JJ, Doe WF. Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem 1995; 227 (1-2): 116-122
• 7 Appella E, Robinson EA, Ullrich SJ. et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262 (10) 4437-4440
• 8 Alfano D, Franco P, Vocca I. et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005; 93 (02) 205-211
• 9 Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front Oncol 2018; 8: 24
• 10 Roldan AL, Cubellis MV, Masucci MT. et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9 (02) 467-474
• 11 Alfano D, Franco P, Stoppelli MP. Modulation of cellular function by the urokinase receptor signalling: A mechanistic view. Front Cell Dev Biol 2022; 10: 818616
• 12 Huai Q, Zhou A, Lin L. et al. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 2008; 15 (04) 422-423
• 13 Mertens HDT, Kjaergaard M, Mysling S. et al. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem 2012; 287 (41) 34304-34315
• 14 Leth JM, Leth-Espensen KZ, Kristensen KK. et al. Evolution and medical significance of LU domain-containing proteins. Int J Mol Sci 2019; 20 (11) 2760
• 15 Degryse B. The urokinase receptor and integrins constitute a cell migration signalosome. In: Edwards D, Høyer-Hansen G, Blasi F, Sloane BF. eds. The Cancer Degradome: Proteases and Cancer Biology. New York, NY: Springer New York; 2008. :pp. 451–474. Accessed September 11, 2025 at: https://doi.org/10.1007/978-0-387-69057-5_23
• 16 Sillen M, Miyata T, Vaughan DE, Strelkov SV, Declerck PJ. Structural insight into the two-step mechanism of PAI-1 inhibition by small molecule TM5484. Int J Mol Sci 2021; 22 (03) 1482
• 17 Sillen M, Declerck PJ. Targeting PAI-1 in cardiovascular disease: Structural insights into PAI-1 functionality and inhibition. Front Cardiovasc Med 2020; 7: 622473 . Accessed September 11, 2025 at: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2020.622473
• 18 Pettersen EF, Goddard TD, Huang CC. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 2004; 25 (13) 1605-1612
• 19 van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, Horrevoets AJG. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997; 90 (05) 1874-1882
• 20 Lawrence DA, Strandberg L, Ericson J, Ny T. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. J Biol Chem 1990; 265 (33) 20293-20301
• 21 Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265 (22) 13029-13035
• 22 Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3 (08) 1879-1883
• 23 Sillen M, Declerck PJ. A narrative review on plasminogen activator inhibitor-1 and its (patho)physiological role: To target or not to target?. Int J Mol Sci 2021; 22 (05) 2721
• 24 Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383 (6599) 441-443
• 25 Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 2000; 297 (03) 683-695
• 26 Mottonen J, Strand A, Symersky J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355 (6357) 270-273
• 27 Gong L, Liu M, Zeng T. et al. Crystal structure of the Michaelis complex between tissue-type plasminogen activator and plasminogen activators inhibitor-1. J Biol Chem 2015; 290 (43) 25795-25804 . Accessed September 11, 2025 at: https://www.sciencedirect.com/science/article/pii/S0021925820495602
• 28 Lin Z, Jiang L, Yuan C. et al. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 2011; 286 (09) 7027-7032 . Accessed September 11, 2025 at: https://www.sciencedirect.com/science/article/pii/S0021925820518978
• 29 Lawrence DA, Ginsburg D, Day DE. et al. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270 (43) 25309-25312 . Accessed September 11, 2025 at: https://www.sciencedirect.com/science/article/pii/S0021925818923203
• 30 Perron MJ, Blouse GE, Shore JD. Distortion of the catalytic domain of tissue-type plasminogen activator by plasminogen activator inhibitor-1 coincides with the formation of stable serpin-proteinase complexes. J Biol Chem 2003; 278 (48) 48197-48203 . Accessed September 11, 2025 at: https://www.sciencedirect.com/science/article/pii/S0021925820758540
• 31 Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407 (6806) 923-926
• 32 Gettins PGW, Olson ST. Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance. Biochem J 2016; 473 (15) 2273-2293
• 33 Dewilde M, Strelkov SV, Rabijns A, Declerck PJ. High quality structure of cleaved PAI-1-stab. J Struct Biol 2009; 165 (02) 126-132 . Accessed September 11, 2025 at: https://www.sciencedirect.com/science/article/pii/S1047847708002670
• 34 Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 1995; 2 (10) 891-897
• 35 Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267 (17) 11693-11696
• 36 Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209 (03) 985-992
• 37 Audenaert AM, Knockaert I, Collen D, Declerck PJ. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J Biol Chem 1994; 269 (30) 19559-19564
• 38 van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, Horrevoets AJG. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997; 90 (05) 1874-1882
• 39 Lawrence DA, Palaniappan S, Stefansson S. et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 1997; 272 (12) 7676-7680
• 40 Declerck PJ, De Mol M, Alessi MC. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263 (30) 15454-15461 . Accessed September 11, 2025 at: https://www.sciencedirect.com/science/article/pii/S0021925819376100
• 41 Komissarov AA, Andreasen PA, Bødker JS, Declerck PJ, Anagli JY, Shore JD. Additivity in effects of vitronectin and monoclonal antibodies against α-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem 2005; 280 (02) 1482-1489
• 42 Preissner KT, Grulich-Henn J, Ehrlich HJ. et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265 (30) 18490-18498
• 43 Jung RG, Simard T, Labinaz A. et al. Role of plasminogen activator inhibitor-1 in coronary pathophysiology. Thromb Res 2018; 164: 54-62
• 44 Binder BR, Christ G, Gruber F. et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002; 17: 56-61
• 45 Carrell RW, Pemberton PA, Boswell DR. The serpins: evolution and adaptation in a family of protease inhibitors. Cold Spring Harb Symp Quant Biol 1987; 52: 527-535
• 46 Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988; 176 (03) 609-616
• 47 Van De Craen B, Declerck PJ, Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012; 130 (04) 576-585
• 48 Pannekoek H, Veerman H, Lambers H. et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986; 5 (10) 2539-2544
• 49 Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986; 83 (18) 6776-6780
• 50 Ginsburg D, Zeheb R, Yang AY. et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78 (06) 1673-1680
• 51 Andreasen PA, Riccio A, Welinder KG. et al. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209 (02) 213-218
• 52 Loskutoff DJ, Linders M, Keijer J, Veerman H, van Heerikhuizen H, Pannekoek H. Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry 1987; 26 (13) 3763-3768
• 53 Providence KM, White LA, Tang J, Gonclaves J, Staiano-Coico L, Higgins PJ. Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. J Cell Sci 2002; 115 (Pt 19): 3767-3777
• 54 Brown NJ, Kim KS, Chen YQ. et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85 (01) 336-344
• 55 van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A 1988; 85 (15) 5525-5529
• 56 Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001; 37 (05) 1336-1340
• 57 Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18 (01) 20-26
• 58 Pont F, Duvillard L, Florentin E, Gambert P, Vergès B. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 2002; 22 (10) 1726-1732
• 59 Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998; 273 (14) 8225-8231
• 60 Song C, Burgess S, Eicher JD, O'Donnell CJ, Johnson AD. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc 2017; 6 (06) e004918
• 61 Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17 (11) 3091-3100
• 62 Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995; 23 (18) 3710-3717
• 63 Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104 (25) 3063-3068
• 64 Huang J, Sabater-Lleal M, Asselbergs FW. et al; DIAGRAM Consortium, CARDIoGRAM Consortium, C4D Consortium, CARDIOGENICS Consortium. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood 2012; 120 (24) 4873-4881
• 65 Koch W, Schrempf M, Erl A. et al. 4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. Thromb Haemost 2010; 103 (06) 1170-1180
• 66 Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets retain high levels of active plasminogen activator inhibitor 1. PLoS ONE 2011; 6 (11) e26762
• 67 Culej Bošnjak D, Balent T, Korać P, Antica M, Matulić M. Urokinase plasminogen activation system modulation in transformed cell lines. Int J Mol Sci 2025; 26 (02) 675
• 68 Ismail AA, Shaker BT, Bajou K. The plasminogen-activator plasmin system in physiological and pathophysiological angiogenesis. Int J Mol Sci 2021; 23 (01) 337
• 69 De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin. EMBO Rep 2016; 17 (07) 982-998
• 70 Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J Cell Biol 1996; 134 (06) 1563-1571
• 71 Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100 (01) 58-67
• 72 Kjøller L, Kanse SM, Kirkegaard T. et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232 (02) 420-429
• 73 Kozlova N, Jensen JK, Chi TF, Samoylenko A, Kietzmann T. PAI-1 modulates cell migration in a LRP1-dependent manner via β-catenin and ERK1/2. Thromb Haemost 2015; 113 (05) 988-998
• 74 Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97 (03) 336-342
• 75 Miszta A, Huskens D, Donkervoort D, Roberts MJM, Wolberg AS, de Laat B. Assessing plasmin generation in health and disease. Int J Mol Sci 2021; 22 (05) 2758 . Accessed September 11, 2025 at: https://research.ebsco.com/linkprocessor/plink?id=5f2e7060-9f50-3319-a570-161dd7908acd
• 76 Mehic D, Reitsma SE, de Moreuil C. et al. Plasmin generation analysis in patients with bleeding disorder of unknown cause. Blood Adv 2024; 8 (21) 5663-5673
• 77 Puster LO, Stanley CB, Uversky VN. et al. Characterization of an extensive interface on vitronectin for binding to plasminogen activator inhibitor-1: Adoption of structure in an intrinsically disordered region. Biochemistry 2019; 58 (51) 5117-5134
• 78 Kihn K, Marchiori E, Spagnolli G. et al. Long-range allostery mediates the regulation of plasminogen activator inhibitor-1 by cell adhesion factor vitronectin. J Biol Chem 2022; 298 (12) 102652
• 79 Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160 (05) 781-791
• 80 Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001; 152 (04) 741-752
• 81 Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10 (01) 39-49
• 82 Høyer-Hansen G, Rønne E, Solberg H. et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267 (25) 18224-18229
• 83 Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000; 470 (01) 40-46
• 84 van Veen M, Matas-Rico E, van de Wetering K. et al. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells. eLife 2017; 6: e23649
• 85 Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16 (24) 7279-7286
• 86 Bifulco K, Votta G, Ingangi V. et al. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. Oncotarget 2014; 5 (12) 4154-4169
• 87 Bifulco K, Longanesi-Cattani I, Franco P. et al. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. PLoS ONE 2012; 7 (09) e44806
• 88 Degryse B, Resnati M, Rabbani SA, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood 1999; 94 (02) 649-662
• 89 Vial D, McKeown-Longo PJ. PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins. J Cell Sci 2008; 121 (Pt 10): 1661-1670
• 90 Sathyamoorthy M, Matta P, Vaughan DE. Loss of PAI-1 through siRNA increases adhesion of monocytes to vitronectin. 2008
• 91 Sathyamoorthy M, Matta P, Vaughan DE. PAI-1 deficiency enhances early outgrowth culture expanded and circulating endothelial progenitor cells: Implications for the fibrinolytic system in stem cell biology. 2008
• 92 Kubala MH, DeClerck YA. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer Metastasis Rev 2019; 38 (03) 483-492
• 93 McCann JV, Xiao L, Kim DJ. et al. Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1. J Clin Invest 2019; 129 (04) 1654-1670
• 94 Bajou K, Masson V, Gerard RD. et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152 (04) 777-784
• 95 Devy L, Blacher S, Grignet-Debrus C. et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16 (02) 147-154
• 96 Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279 (21) 22595-22604
• 97 Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88 (03) 887-918
• 98 Czekay RP, Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol 2009; 220 (03) 655-663
• 99 Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60 (20) 5839-5847
• 100 Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111 (02) 783-792
• 101 Kamikubo Y, Neels JG, Degryse B. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. Int J Biochem Cell Biol 2009; 41 (03) 578-585
• 102 Hou SX, Zheng Z, Chen X, Perrimon N. The Jak/STAT pathway in model organisms: emerging roles in cell movement. Dev Cell 2002; 3 (06) 765-778
• 103 Czekay RP, Wilkins-Port CE, Higgins SP. et al. PAI-1: An integrator of cell signaling and migration. Int J Cell Biol 2011; 2011: 562481
• 104 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3 (12) 932-943
• 105 He Z, Wang G, Wu J, Tang Z, Luo M. The molecular mechanism of LRP1 in physiological vascular homeostasis and signal transduction pathways. Biomed Pharmacother 2021; 139: 111667
• 106 Ma Z, Thomas KS, Webb DJ. et al. Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J Cell Biol 2002; 159 (06) 1061-1070
• 107 Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem 1997; 272 (45) 28563-28567
• 108 Dumler I, Weis A, Mayboroda OA. et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273 (01) 315-321
• 109 Dumler I, Kopmann A, Wagner K. et al. Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J Biol Chem 1999; 274 (34) 24059-24065
• 110 Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72 (01) 1-22
• 111 Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH. [The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]. Mund Kiefer Gesichtschir 2004; 8 (03) 173-179
• 112 Durand MKV, Bødker JS, Christensen A. et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91 (03) 438-449
• 113 Kelly TE, Spillane CL, Ward MP. et al. Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy. Front Cell Dev Biol 2023; 11: 1150991
• 114 Chen SC, Henry DO, Reczek PR, Wong MKK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 2008; 7 (05) 1227-1236
• 115 Morita Y, Hayashi Y, Kanamaru T. et al. Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells. Jpn J Cancer Res 1999; 90 (07) 747-752
• 116 Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ. PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res 2014; 12 (03) 322-334
• 117 Mashiko S, Kitatani K, Toyoshima M. et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther 2015; 16 (02) 253-260
• 118 Li CF, Kandel C, Baliko F, Nadesan P, Brünner N, Alman BA. Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor). Oncogene 2005; 24 (09) 1615-1624
• 119 Vial D, Monaghan-Benson E, McKeown-Longo PJ. Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells. Cancer Cell Int 2006; 6: 8
• 120 McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood 2010; 116 (23) 5037-5044
• 121 McEachron TA, Church FC, Mackman N. Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells. Blood Coagul Fibrinolysis 2011; 22 (07) 576-582
• 122 Mazzieri R, Blasi F. The urokinase receptor and the regulation of cell proliferation. Thromb Haemost 2005; 93 (04) 641-646
• 123 Soeda S, Shinomiya K, Ochiai T. et al. Plasminogen activator inhibitor-1 aids nerve growth factor-induced differentiation and survival of pheochromocytoma cells by activating both the extracellular signal-regulated kinase and c-Jun pathways. Neuroscience 2006; 141 (01) 101-108
• 124 Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8 (08) 877-884
• 125 Rana T, Jiang C, Banerjee S. et al. PAI-1 regulation of p53 expression and senescence in type II alveolar epithelial cells. Cells 2023; 12 (15) 2008
• 126 Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK. Plasminogen activator inhibitor-1 is a marker and a mediator of senescence. Arterioscler Thromb Vasc Biol 2017; 37 (08) 1446-1452
• 127 Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63 (07) 1684-1695
• 128 Beaulieu LM, Whitley BR, Wiesner TF. et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. BioEssays 2007; 29 (10) 1029-1038
• 129 Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 2008; 100 (06) 1037-1040
• 130 Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 2012; 104 (19) 1470-1484
• 131 Valiente M, Obenauf AC, Jin X. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014; 156 (05) 1002-1016
• 132 Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66
• 133 Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 2008; 100 (06) 1029-1036
• 134 Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 2006; 281 (32) 22527-22536
• 135 Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 2006; 281 (26) 17758-17767
• 136 Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002; 277 (16) 14040-14047
• 137 Balsara RD, Xu Z, Ploplis VA. Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice. Curr Drug Targets 2007; 8 (09) 982-995
• 138 Cajot JF, Bamat J, Bergonzelli GE. et al. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A 1990; 87 (18) 6939-6943
• 139 Alizadeh H, Ma D, Berman M. et al. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 1995; 14 (06) 449-458
• 140 Bajou K, Maillard C, Jost M. et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004; 23 (41) 6986-6990
• 141 Chen H, Peng H, Liu W. et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery 2015; 158 (06) 1704-1713
• 142 Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2013; 39 (04) 382-391
• 143 Bajou K, Peng H, Laug WE. et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14 (04) 324-334
• 144 Olander JV, Bremer ME, Marasa JC, Feder J. Fibrin-enhanced endothelial cell organization. J Cell Physiol 1985; 125 (01) 1-9
• 145 Qi J, Goralnick S, Kreutzer DL. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood 1997; 90 (09) 3595-3602
• 146 Inoue M, Sawada T, Uchima Y. et al. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep 2005; 14 (06) 1445-1451
• 147 Marshall LJ, Ramdin LSP, Brooks T, DPhil PC, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003; 171 (04) 2057-2065
• 148 Kubala MH, Punj V, Placencio-Hickok VR. et al. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep 2018; 25 (08) 2177-2191.e7

Publikationsverlauf

Eingereicht: 24. Januar 2025

Angenommen: 15. Juli 2025

Accepted Manuscript online:
10. September 2025

Artikel online veröffentlicht:
26. September 2025